---
document_datetime: 2023-12-20 17:33:47
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/defitelio-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: defitelio-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 13.1858503
conversion_datetime: 2025-12-15 22:05:33.84145
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Defitelio

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                           |
|----------------------|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------|
| IB/0063              | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product | 19/12/2023                          |                                             | SmPC, Labelling and PL           |                                                                                                                   |
| R/0061               | Renewal of the marketing authorisation.                                                                                  | 30/03/2023                          | 26/05/2023                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        | Defitelio in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0060    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/03/2023 | n/a        |                        |                                                                                                                                                         |
| II/0059   | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                  | 12/01/2023 | n/a        |                        |                                                                                                                                                         |
| II/0058/G | This was an application for a group of variations. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission              | 07/07/2022 | n/a        |                        |                                                                                                                                                         |
| S/0057    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 22/04/2022 | 24/06/2022 | Annex II               |                                                                                                                                                         |
| II/0056   | Submission of the final report from study 15-007 listed as a specific obligation in the Annex II of the Product Information. This is a phase 3, randomised, adaptive study (15-007) of Defibrotide vs. best supportive care in the prevention of hepatic veno- occlusive disease in adult and paediatric patients undergoing hematopoietic stem cell transplant (HSCT). The RMP version 9 has also been submitted. The MAH has also taken the opportunity to align the | 19/05/2022 | 24/06/2022 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Defitelio-II-56' For more information, please refer to the Summary of Product Characteristics.                   |

<div style=\"page-break-after: always\"></div>

|                     | PI to the latest QRD template 10.2 which replaces the United Kingdom with United Kingdom (Northern Ireland) in the PIL. In addition, the MAH is correcting the following errata during the linguistic review of the PI: correction of the paragraph number for Regulation (EC) No 726.2004 which was cited incorrectly in Annex II of the French PI and formatting updates to Norwegian and Swedish language PIs. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10086 /202010 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/06/2021 | n/a | PRAC Recommendation - maintenance |
| IB/0055             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 20/04/2021 | n/a |                                   |
| IB/0054             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/03/2021 | n/a |                                   |
| S/0051              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/02/2021 | n/a |                                   |
| IB/0052             | B.I.a.2.z - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29/01/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                  |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IB/0050 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/12/2020 | 22/09/2021 | Annex II                         |
| IB/0049 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 14/10/2020 | 22/09/2021 | SmPC and PL                      |
| II/0048 | Update the RMP version 8.0 in line with PRAC recommendations, following approval of PBRER 12 (EMEA/H/C/PSUSA/00010086/201910), to update section SVII 2, Safety Concerns and Reclassification for removal of the Important Potential Risks and Missing Information from the RMP: Injection site reactions/infections, including septicaemia as a serious complication of these reactions/infections; Immunogenicity (generation of anti-nuclear antibodies); Use in patients with grade B-D GvHD; Use in patients with ethnic background other than Caucasian; use in patients >65 years of age and off- label use; the RMP has been also updated with the results of study (DF VOD 2013 03 REG). Furthermore, the Marketing Authorisation Holder took the opportunity to: · Update Sub-section Cardiac Electrophysiology in section 5.1 of Annex I (SmPC) to correct a typographical error; · Introduce other minor editorial and QRD updates throughout Annexes I-III; | 17/09/2020 | 22/09/2021 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|                     | warning for medicinal products containing Sodium. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                        |            |            |          |                                                                                                                                                                                                                                                                    |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0047              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                           | 18/05/2020 | 22/09/2021 | PL       |                                                                                                                                                                                                                                                                    |
| PSUSA/10086 /201910 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                  | 14/05/2020 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| S/0045              | 6th annual re-assessment                                                                                                                                                                                                                   | 27/02/2020 | n/a        |          | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Defitelio should be maintained. |
| PSUSA/10086 /201904 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                  | 31/10/2019 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| IB/0044             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 07/10/2019 | n/a        |          |                                                                                                                                                                                                                                                                    |
| II/0043             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                              | 19/09/2019 | 01/04/2020 | Annex II |                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| S/0038              | Annual re-assessment.                                                                                                                                                                                                                                                                               | 28/03/2019   | 11/07/2019   | Annex II                         |                                                                                                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10086 /201810 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                           | 16/05/2019   | n/a          |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                |
| II/0039             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                   | 02/05/2019   | 01/04/2020   | SmPC                             |                                                                                                                                                                                                                                                  |
| N/0041              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                    | 26/03/2019   | 11/07/2019   | PL                               |                                                                                                                                                                                                                                                  |
| N/0037              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                    | 20/12/2018   | 11/07/2019   | Labelling                        |                                                                                                                                                                                                                                                  |
| PSUSA/10086 /201804 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                           | 31/10/2018   | n/a          |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                |
| IA/0035/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 24/09/2018   | n/a          |                                  |                                                                                                                                                                                                                                                  |
| R/0032              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                             | 26/04/2018   | 26/07/2018   | SmPC, Annex II, Labelling and PL | Based upon the data that have become available since the granting of the initial Marketing authorisation, the CHMP considers that the benefit-risk balance of Defitelio remains positive, but considers that its safety profile is to be closely |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |          | monitored for the following reasons: The specific obligation to set up a patient registry to investigate long-term safety, health outcomes and patterns of utilisation of defibrotide under normal use has not been fulfilled and post-marketing experience remains limited, particularly with respect to long-term safety. Therefore, the CHMP decided that the MAH should continue to collect long- term safety information about Defitelio, as described in annex II. Therefore, based upon the safety profile of Defitelio, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.                                                                                                                                                                                                                                                                                             |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027 | Submission of an update RMP version 4.3 in order to replace the remaining imposed non-interventional PASS (an observational registry, study DF-VOD2013- 03-REG, which aims to record safety and outcome data in patients diagnosed with severe VOD following hematopoietic stem cell transplant (HSCT) treated or not with Defitelio) listed as a category 2 study in the RMP (specific obligation 001) by two new specific obligations: one to provide comparative safety data based on the final results of study 15-007 (a phase 3, randomised, adaptive study of defibrotide versus best supportive care in the prevention of hepatic veno-occlusive disease in adult and paediatric patients undergoing HSCT); the other to provide comparative data on efficacy based on a systematic literature reviews and analyses, and on data analysis from Center for International Blood and Marrow Transplant Research (CIBMTR) for patients treated and not treated with defibrotide. The Annex II.E of | 28/06/2018 | 11/07/2019 | Annex II | Following the MAH's request to consider SOB 001as fulfilled as this non-interventional PASS was considered by the MAH as no longer feasible in its current form due to ethical concerns in recruiting patients to the control arm, the CHMP concluded that based on the data provided, the currently available clinical study and post-marketing data cannot be considered as having adequately address the outstanding specific obligation for Defitelio. Therefore the current SOB 001 is being replaced by two new SOBs: an ongoing randomised phase 3 trial of Defitelio against best supportive care for prevention of VOD in patients (adults and paediatrics) undergoing HSCT (study 15-007) in order to collect comparative safety data and a systematic literature review, in conjunction with a data analyses from international blood and marrow transplantation registries, to collect comparative efficacy data. |

<div style=\"page-break-after: always\"></div>

|                     | the product information is updated accordingly. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10086 /201710 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/05/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0033             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 24/04/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0026             | Update of sections 4.8 and 5.1 of the SmPC in order to update the frequencies of adverse reactions included in the tabulated list of adverse reactions and to update the clinical efficacy and safety information based on the results from study 2006-05 listed as category 3 in the risk management plan (RMP). This is a phase 3, open-label expanded access study designed to provide access to defibrotide as an investigational new drug to patients with severe hepatic veno-occlusive disease. The final study report has been submitted. The RMP (version 3.4) and package leaflet are updated accordingly. In addition, the MAH took the opportunity to bring the | 12/04/2018 | 26/07/2018 | SmPC, Labelling and PL | Based on the results of the open label treatment IND study, the complete response by Day+100 has been revised to 39.3% (201/512) and the survival has been revised to 49.5% (*Kaplan Meier estimates for time-to-event analysis by Day+100) in section 5.1 of the SmPC. In addition, the frequencies of the adverse drug reactions have been revised. In section 4.8 of the SmPC, the tabulated list of adverse reactions incorporates the adverse drug reactions (ADRs) observed in study 2005-01 [ADR = any event reported as possibly related on at least two occasions] and treatment emergent adverse events (TEAEs) observed in T-IND 2006-05 study [TEAE = any AE that started or worsened in severity after the first dose of |

<div style=\"page-break-after: always\"></div>

|           | SmPC in line with the latest QRD template (version 10), to update the list of local representatives in the package leaflet and to correct a translation error in the Polish, Finnish, Danish and Latvian languages. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                              |            |     | defibrotide]. For adverse reactions reported in both studies, the highest frequency was used in the tabulated list of adverse reactions. The safety data from the pivotal study are supported and confirmed with data from the completed Treatment-IND study.                                          |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0029    | 4th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/03/2018 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that the marketing authorisation of Defitelio should be maintained under exceptional circumstances. |
| IA/0031/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier | 24/01/2018 | n/a |                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| PSUSA/10086 /201704   | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/10/2017   | n/a        |    | PRAC Recommendation - maintenance   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-------------------------------------|
| IB/0028               | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 04/10/2017   | n/a        |    |                                     |
| IB/0025/G             | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 21/09/2017   | n/a        |    |                                     |
| PSUSA/10086 /201610   | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/05/2017   | n/a        |    | PRAC Recommendation - maintenance   |
| N/0023                | Minor change in labelling or package leaflet not                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21/04/2017   | 26/07/2018 | PL |                                     |

<div style=\"page-break-after: always\"></div>

|                     | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| S/0020              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/04/2017 | n/a |                                   |
| IB/0022             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/03/2017 | n/a |                                   |
| PSUSA/10086 /201604 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 27/10/2016 | n/a | PRAC Recommendation - maintenance |
| II/0019             | Submission of a revised RMP in order to include information regarding the additional risk minimisation measures (i.e. Healthcare professional material that highlights the existence of the Registry as well as the means to enter patients into the registry) as outlined in Annex II. In addition, the MAH took the opportunity to add administrative changes to the protocol of the registry study, to add information about the renal pharmacokinetics study, to add updated information about off-label use during post-marketing experience and to include further administrative changes to the RMP. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 13/10/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0017/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   | 11/08/2016   | n/a        |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012     | Update of sections 4.2, 4.9 and 5.2 of the SmPC based on information from a pharmacokinetic study in patients with renal impairment. Further, corrections to existing information on plasma protein binding and excretion of defibrotide are introduced in section 5.2 of the SmPC. In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the SmPC and Annex II in line with the latest QRD template version 9.1. Moreover, section 6.4 of the SmPC has been amended to comply with QRD template and CHMP guideline on declaration of storage conditions. C.I.4 - Change(s) in the SPC, Labelling or PL due to              | 26/05/2016   | 11/01/2017 | SmPC and Annex II | In vitro studies demonstrate that 93% of Defitelio is bound to plasma proteins. After administration of the therapeutic dose (6.25 mg/kg) to healthy subjects, an average of 9.48% of the total dose administered is excreted in urine as unchanged defibrotide in 24 hours, with the majority excreted during the first collection interval of 0-4 hours (approximately 98%). Accumulation of defibrotide over 4 doses was not found. Difference in exposure is not considered clinically relevant and so dose adjustment is not required for patients with renal impairment or who are on intermittent haemodialysis. Defibrotide is not removed by dialysis. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  |                                                                                                                                                                                                                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10086 /201510 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 13/05/2016 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| S/0013              | 2nd Annual Re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/04/2016 | n/a        |                                  | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Defitelio should be maintained. |
| IB/0016             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/03/2016 | 11/01/2017 | SmPC and PL                      |                                                                                                                                                                                                                                                                    |
| IAIN/0015/G         | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the | 05/02/2016 | 11/01/2017 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | PSMF location                                                                                                                                                                                                                                                                                                                                                                 |            |     |                                                                                                                                                                                                                                                                    |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10086 /201504 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                     | 06/11/2015 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| IAIN/0011           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                               | 16/07/2015 | n/a |                                                                                                                                                                                                                                                                    |
| IA/0009/G           | This was an application for a group of variations. B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor | 06/07/2015 | n/a |                                                                                                                                                                                                                                                                    |
| PSUSA/10086 /201410 | Periodic Safety Update EU Single assessment - defibrotide                                                                                                                                                                                                                                                                                                                     | 07/05/2015 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| S/0005              | 1st Annual Re-assessment.                                                                                                                                                                                                                                                                                                                                                     | 23/04/2015 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Defitelio should be maintained. |
| IAIN/0008/G         | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                            | 10/04/2015 | n/a |                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IA/0007/G | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.6 - Administrative change - Change in ATC | 11/03/2015 | 28/01/2016 | SmPC |

<div style=\"page-break-after: always\"></div>

| II/0002/G   | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.e - Stability of FP - Change to an approved stability protocol   | 22/01/2015   | 28/01/2016   | SmPC and Annex II   |                                                                                                                                                                                                                  |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0003   | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/11/2014   | n/a          |                     | PRAC Recommendation - maintenance                                                                                                                                                                                |
| IAIN/0004   | C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities                                                                                                                                                                                                                                                                                                                                                                                                                                          | 17/09/2014   | n/a          |                     |                                                                                                                                                                                                                  |
| II/0001     | Update of section D of Annex II of the Product Information in order to fulfil a post-authorisation measure to submit additional information from the CIBMTR registry database concerning baseline                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/03/2014   | 12/01/2015   | Annex II            | The company has submitted data from the Centre for International Blood and Marrow Transplant registry database in order to fulfil a post-approval measure.There were some imbalances that have been noted in the |

<div style=\"page-break-after: always\"></div>

| characteristics from treated patients. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | baseline characteristics. The most notable imbalances appear to be age where 61% of the defibrotide group were under 16yrs old and 20% of the control group were 16yrs old and over and gender where 46% of the defibrotide group were male and 72% of the control group were female.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|